publication venue for
- A signature of enhanced proliferation associated with response and survival to anti-PD-L1 therapy in early-stage non-small cell lung cancer. 2024
- The gut microbiome regulates the clinical efficacy of sulfasalazine therapy for IBD-associated spondyloarthritis. 2024
- Single-cell transcriptomics of the immune system in ME/CFS at baseline and following symptom provocation.. 5. 2024
- A target discovery pipeline identified ILT3 as a target for immunotherapy of multiple myeloma.. 4. 2023
- Development of an artificial intelligence-derived histologic signature associated with adjuvant gemcitabine treatment outcomes in pancreatic cancer.. 4. 2023
- Germline-targeting HIV-1 Env vaccination induces VRC01-class antibodies with rare insertions. 2023
- Harnessing transcriptionally driven chromosomal instability adaptation to target therapy-refractory lethal prostate cancer.. 4. 2023
- Inherited mutations in Chinese patients with upper tract urothelial carcinoma.. 4. 2023
- Mucosal-homing natural killer cells are associated with aging in persons living with HIV. 2022
- Broad and ultra-potent cross-clade neutralization of HIV-1 by a vaccine-induced CD4 binding site bovine antibody.. 3. 2022
- System-wide transcriptome damage and tissue identity loss in COVID-19 patients.. 3. 2022
- Molecular predictors of response to pembrolizumab in thymic carcinoma.. 2. 2021
- A recombinant bovine adenoviral mucosal vaccine expressing mycobacterial antigen-85B generates robust protection against tuberculosis in mice.. 2. 2021
- Different evolutionary pathways of HIV-1 between fetus and mother perinatal transmission pairs indicate unique immune selection in fetuses.. 2. 2021
- ACCELERATE: A Patient-Powered Natural History Study Design Enabling Clinical and Therapeutic Discoveries in a Rare Disorder.. 1. 2020
- DNA Repair Gene Mutations as Predictors of Immune Checkpoint Inhibitor Response beyond Tumor Mutation Burden.. 1. 2020
- Co-targeting TGF-β and PD-L1 with radiation therapy: The Goldilocks principle. 2021
- Artificial intelligence and open science in discovery of disease-modifying medicines for Alzheimer's disease. 2024
- Deep generative molecular design reshapes drug discovery. 2022